[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654559":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":39,"armGroups":43,"interventions":50,"overallOfficials":39,"centralContacts":56,"locations":62,"responsibleParty":74,"collaborators":76,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":39,"studyType":92,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":102,"whyStopped":39,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"National University Hospital, Singapore","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Beck Anxiety Inventory (BAI)","The primary outcome will be the response rate as defined as ≥50% reduction from baseline BAI scores pre- and post-iTBS treatment. BAI is an ordinal self-report scale measuring physical and cognitive anxiety symptoms ranging from 0-63. Higher scores mean worse outcome.","Baseline, immediately post-treatment, 1-month and 3-months post-intervention.",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Beck Depression Inventory (BDI)","Change in BDI scores pre- and post-iTBS treatment. BDI is an ordinal self-report scale measuring depressive symptoms ranging from 0-63. Higher scores mean worse outcome.",{"measure":18,"description":19,"timeFrame":12},"Penn State Worry Questionnaire (PSWQ)","Change in PSWQ scores pre- and post-iTBS treatment. PSWQ is an ordinal self-report scale measuring pathological worry ranging from 16-80. Scores depend on whether the item is worded positively or negatively.",{"measure":21,"description":22,"timeFrame":12},"Mini-Mood and Anxiety Symptom Questionnaire (Mini-MASQ)","Change in Mini-MASQ scores pre- and post-iTBS treatment. The Mini-MASQ is an orginal self-report scale measuring symptoms of anxiety and depression. Scores depend on whether the item is worded positively or negatively.",{"measure":24,"description":25,"timeFrame":12},"Hamilton Anxiety Rating Scale (HAM-A)","Change in HAM-A scores pre- and post-iTBS treatment. HAM-A is an ordinal clinician-rated scale measuring severity of psychic and somatic anxiety, ranging from 0-56. Higher scores mean a worse outcome.",{"measure":27,"description":28,"timeFrame":12},"Inventory of Depression and Anxiety Symptoms-II (IDAS-II)","Change in IDAS-II scores pre- and post-iTBS treatment. IDAS-II is an ordinal self-report scale measuring depression, anxiety, and bipolar symptoms ranging from 99-495. Higher scores mean worse outcome.",{"measure":30,"description":31,"timeFrame":12},"Sheehan Disability Scale (SDS)","Change in SDS scores pre- and post-iTBS treatment. SDS is an ordinal self-report scale measuring how symptoms affect functional imapirment across work\u002F school, social life, and family\u002F home responsibilities, ranging from 0-10 for each domain. Higher scores mean a worse outcome.",[33],{"measure":34,"description":35,"timeFrame":12},"Correlation of changes in functional connectivity with changes in BAI scores","The investigators will perform additional exploratory post-hoc analyses by analysing brain imaging changes before and after TMS treatment.",{"allocation":37,"interventionModel":38,"interventionModelDescription":39,"primaryPurpose":40,"observationalModel":39,"timePerspective":39,"maskingInfo":41},"NA","SINGLE_GROUP",null,"TREATMENT",{"masking":42,"maskingDescription":39,"whoMasked":39},"NONE",[44],{"label":45,"type":46,"description":47,"interventionNames":48},"Individualized neuronavigated intermittent theta burst stimulation (MagPro X100) system for anxiety","EXPERIMENTAL","Participants will receive an accelerated intermittent theta burst stimulation (iTBS) treatment delivered with a MagVenture MagPro X100 system (MagVenture A\u002FS, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A\u002FP coil. The treatment course is comprised of 6 treatment sessions daily for 5 consecutive workdays for a total of 30 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.",[49],"Device: Individually Neuronavigated accelerated intermittent theta burst stimulation with MagPro X100",[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":39},"DEVICE","Individually Neuronavigated accelerated intermittent theta burst stimulation with MagPro X100","Magpro X100, Axilium Cobot, Localite Camera",[45],[57],{"name":58,"role":59,"phone":60,"phoneExt":39,"email":61},"Phern Chern Tor, MBBS","CONTACT","+65 6908 2222","cip@nuhs.edu.sg",[63],{"facility":5,"status":39,"city":64,"state":39,"zip":39,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Singapore","SG",{"type":67,"coordinates":68},"Point",[69,70],103.85007,1.28967,{"lat":70,"lon":69},[73],{"name":58,"role":59,"phone":60,"phoneExt":39,"email":61},{"type":75,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[77],{"name":78,"class":6},"National University of Singapore","100654559","personalized-and-accelerated-transcranial-magnetic-stimulation-for-treatment-resistant-anxiety-related-disorders-100654559",false,"NCT07801391","Personalized and Accelerated Transcranial Magnetic Stimulation for Treatment-resistant Anxiety Related Disorders","I2Start","Inclusion Criteria:\n\n* Male\u002F female aged ≥ 21 years and ≤ 70 years\n* Diagnosis of an anxiety-related disorder as validated by the MINI (Specifically, the types of anxiety-related disorders are: generalized anxiety disorder; panic disorderl social anxiety disorder; obsessive compulsive disorder; post-traumatic stress disorder; agoraphobia; anxiety disorder due to another medical condition; other specified anxiety disorders; and unspecified anxiety disorder.)\n* Non-response to adequate trial (4 weeks) of at least two anxiety medication as verified by the study clinician, or psychotherapy for anxiety\n* BAI score of 16 or above\n* Able to give informed consent\n* Able to understand English\n\nExclusion Criteria:\n\n* DSM-5 psychotic disorder\n* Significant personality disorder which may hinder the progress of this study\n* Drug or alcohol abuse or dependency (preceding 3 months)\n* Rapid clinical response required, e.g., high suicide risk\n* Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy\n* Metal in the cranium, skull defects, pacemaker, cochlear implant, medication infusion pumps or any other electronic implants\u002F devices\n* Tattoos containing derromagnetic ink or permanent piercings\n* Currently wearing dental braces\n* Pregnancy\n* Unsuitable for MRI or TMS for any other reasons\n* With recent TMS or ECT treatment within the past 3 months\n* Currently on multiple stimulant medications (2 or more)\n* Participant does not have the capacity to provide consent","ALL","21 Years","70 Years",{"count":90,"type":91},24,"ESTIMATED","INTERVENTIONAL",[37],"This proposal seeks to carry out an open-label single arm study to examine the neurobehavioral changes induced by personalized, causal network mapping guided accelerated intermittent theta burst stimulation (aiTBS) in patients with treatment-resistant anxiety-related disorders.",[96],"Anxiety and Fear-Related Disorders",[98,99,100,101],"Anxiety","Neuronavigated","iTBS","Accelerated","NOT_YET_RECRUITING","2026-08-31",{"date":105,"type":106},"2026-09-03","ACTUAL",{"date":108,"type":91},"2026-09",{"date":110,"type":91},"2029-12",{"name":5,"class":6},1]